The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immuno-oncology therapy.
The guideline includes a draft summary of six recommendations, which CAP said is now available for an open comment period from March 31 to April 23, 2021.
“Given the rapid evolution of immunotherapy and immunomodulatory drugs, pathologists have a need to develop universally accepted, standardized criteria for immunohistochemistry (IHC)-based testing of immune checkpoint proteins, particularly for PD-L1,” explained project co-chair Lynette Sholl, MD, FCAP, Pathologist at Brigham and Women’s Hospital.
The expert panel will consider all comments garnered during the comment period before finalizing the recommendations and submitting the guideline for publication.
